COPENHAGEN, Denmark, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ: FWP ) (the “Company”), a biopharmaceutical company working to advance a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications, today announced that Joel Sendek, the Company’s Chief Financial Officer, will participate in the following conferences:
- Wells Fargo Securities Healthcare Conference to be held at the Westin Boston Waterfront in Boston, Massachusetts. Mr. Sendek will host one-on-one meetings on Wednesday, September 7 th .
- Morgan Stanley Healthcare Conference to be held at the Grand Hyatt in New York, New York. Mr. Sendek will present on Monday, September 12th at 4:50 PM EDT.
- Mizuho Therapeutics Conference to be held at the Langham Hotel in Boston, Massachusetts. Mr. Sendek will host one-on-one meetings on Wednesday, September 21st.
Investors and other interested parties may access a live audio webcast of our conference presentation by visiting the investor page on the Company’s website ( www.forward-pharma.com ). The audio replay will be available via our website for 90 days following the presentation.
About Forward Pharma: Forward Pharma A/S is a Danish biopharmaceutical company developing FP187, a proprietary formulation of DMF (dimethyl fumarate) for the treatment of inflammatory and neurological indications. Since our founding in 2005, we have worked to advance unique formulations of DMF, which is an immune modulator, as a therapeutic agent to improve the health and well-being of patients with immune disorders including multiple sclerosis. FP187, our clinical candidate, is a DMF formulation in a delayed and slow release oral dose.
Our principal executive offices are located at Østergade 24A, 1st Floor, 1100 Copenhagen K, Denmark and our American Depositary Shares are publicly traded on NASDAQ Stock Market (FWP). For more information about the Company’s products and developments, please visit our web site at http://www.forward-pharma.com .
Forward Pharma A/S Media Contact: Sharon Klahre, Director, Investor Relations Forward Pharma USA, LLC 7 Skyline Drive Hawthorne, NY 10532 SK@forward-pharma.com +1 914-752-3542
The Ruth Group Lee Roth lroth@theruthgroup.com +1 646-536-7014
Forward Looking Statements: Certain statements in this press release or in the above-referenced presentations may constitute “forward-looking statements” of the Company within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements which contain language such as “believe,” “expect,” “anticipate,” “hope,” “would” and “potential.” Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company’s ability to obtain, maintain and defend issued patents with protective claims; the issuance and term of patents; the Company’s ability to prevail in or obtain a favorable decision in any patent interference or infringement action; the Company’s ability to recover damages in any patent infringement action; uncertainties relating to our development plans and activities, including the commencement of any clinical trial and the results, timing, cost and location thereof; risks and uncertainties related to the scope, validity and enforceability of our intellectual property rights in general and the impact on us of patents and other intellectual property rights of third parties; our ability to commercialize and generate revenue from our sole clinical candidate, FP187; clinical development, and clinical trials of FP187 may not be successful; completion of required clinical trials may take longer than we anticipate, which could result in increased costs, limit our access to funding and delay or limit our ability to obtain regulatory approval for FP187; and our evaluation of alternative Phase 3 clinical strategies in RRMS may not be successful or shorten our time to commercialization and/or reduce costs. These and other factors are identified and described in detail in certain of our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2015.
